What are the most common to least common side effects of donepezil (Aricept) in older adults being treated for dementia?

Side Effects of Donepezil: Most Common to Least Common

The most common side effects of donepezil are gastrointestinal—specifically nausea (11% vs 6% placebo), diarrhea (10% vs 5% placebo), and vomiting (5% vs 3% placebo)—followed by neuropsychiatric effects including insomnia (9% vs 6% placebo) and dizziness (8% vs 6% placebo), with muscle cramps (6% vs 2% placebo) also occurring frequently. 1

Most Common Side Effects (≥5% incidence and twice placebo rate)

Gastrointestinal Effects (Most Frequent)

• Nausea occurs in approximately 11% of patients on donepezil versus 6% on placebo, with a relative risk of 2.54 2, 3, 1
• Diarrhea affects 10% of donepezil patients versus 5% on placebo, with a relative risk of 2.57 4, 2, 3, 1
• Vomiting occurs in 5% versus 3% on placebo 1
• Anorexia has the largest effect size among gastrointestinal symptoms with a relative risk of 3.21, affecting 4% versus 2% on placebo 2, 3, 1

Neuropsychiatric Effects

• Insomnia occurs in 9% of patients versus 6% on placebo 2, 1
• Dizziness affects 8% versus 6% on placebo, with a relative risk of 1.47 2, 3, 1
• Abnormal dreams occur more frequently with donepezil, particularly in vascular dementia patients 2, 3

Musculoskeletal Effects

• Muscle cramps (particularly leg cramps) occur in 6% versus 2% on placebo, with an extremely high relative risk of 9.62 in vascular dementia patients 2, 3, 1

Constitutional Symptoms

• Fatigue affects 5% versus 3% on placebo 1

Less Common Side Effects (2-5% incidence)

• Headache occurs in 10% versus 9% on placebo 1
• Pain (various locations) affects 9% versus 8% on placebo 1
• Accident/falls occur in 7% versus 6% on placebo 1
• Depression affects 3% versus <1% on placebo 1
• Weight decrease occurs in 3% versus 1% on placebo 1
• Ecchymosis (bruising) affects 4% versus 3% on placebo 1
• Syncope occurs in 2% versus 1% on placebo 1
• Somnolence affects 2% versus <1% on placebo 1
• Frequent urination occurs in 2% versus 1% on placebo 1
• Arthritis affects 2% versus 1% on placebo 1

Uncommon Side Effects (<2% incidence)

• Agitation may increase initially but typically resolves within the first few weeks of therapy 2, 5
• Aggression is uncommonly associated with donepezil 5
• Bradyarrhythmia can occur, requiring caution in patients with cardiac conduction abnormalities 3, 6

Critical Dose-Response Relationship

Six clinical studies demonstrated a clear dose-response effect: adverse events increase significantly when escalating from 5 mg to 10 mg daily. 4, 2

Comparative Rates by Dose (at 10 mg/day with 1-week titration vs 6-week titration):

• Nausea: 19% (rapid titration) versus 6% (slow titration) 1
• Diarrhea: 15% (rapid titration) versus 9% (slow titration) 1
• Insomnia: 14% (rapid titration) versus 6% (slow titration) 1
• Vomiting: 8% (rapid titration) versus 5% (slow titration) 1
• Muscle cramps: 8% (rapid titration) versus 3% (slow titration) 1
• Fatigue: 8% (rapid titration) versus 3% (slow titration) 1
• Anorexia: 7% (rapid titration) versus 3% (slow titration) 1

Withdrawal Rates

• Discontinuation due to adverse events ranges from 5% at the 5 mg dose (comparable to placebo) to 13% at the 10 mg dose with rapid titration 1, 7
• The most common adverse events leading to discontinuation (≥2% and twice placebo) are nausea (3% vs 1% placebo), diarrhea (3% vs <1% placebo), and vomiting (2% vs <1% placebo) 1

Serious Adverse Events

High-quality systematic reviews found no statistically significant difference in serious adverse events between donepezil and placebo, aside from expected cholinergic side effects. 4, 2, 7

• Serious adverse event rates are comparable between donepezil (4-10%) and placebo (5-9%) 2
• No hepatotoxicity has been attributed to donepezil, unlike older cholinesterase inhibitors such as tacrine 2, 3, 6
• No cardiac rhythm disturbances or liver disorders have been causally associated with donepezil 5

Key Mitigation Strategies

• Take donepezil with food to reduce gastrointestinal side effects 2
• Use gradual dose titration (increase from 5 mg to 10 mg after 4-6 weeks, not 1 week) to minimize adverse events 2, 1
• Most adverse events are mild, transient, and resolve during continued treatment without requiring dose modification 1, 6
• Initial agitation typically subsides after the first few weeks and does not require discontinuation 2

Important Drug Interactions

• Potential interactions exist with cimetidine, theophylline, warfarin, and digoxin, requiring close monitoring when initiating donepezil 2, 3